Malorye wrote back in November that the future of BiDil, the controversial heart-failure drug approved specifically for African Americans, was resting on a new marketing plan from manufacturer NitroMed (NASDAQ: NTMD). Looks like that plan has failed. The Lexington, MA-based firm announced yesterday after the market’s close that it was slashing its staff from 90 to 20 and discontinuing promotional efforts for the drug (although it will continue to make BiDil available to patients). NitroMed is continuing development of a once-daily version of the drug, but doesn’t plan to file for approval of that product until 2010.
Why is this story so short? Because it's a news brief
from our News Xpress section,
which brings you quick takes on
the latest Boston-area biz/tech news as it unfolds throughout
the day.
Where do I find more in-depth news and analysis about the
business of technology in the Boston area? We've got
plenty of that right on our
home page and in our
archives.
Who the heck are the Xconomists mentioned on your
homepage? They're an elite group of movers and shakers in
the local tech scene who've generously agreed to share
their insights and opinions with Xconomy's readers. Here's a
complete list of them; to read their posts, have a look
here and
here.
Come to think of it, what does "Xconomy" mean in the
first place? Xconomy is a word we made up to evoke the
exponential economy—the realm of business and innovation
characterized by exponential technological growth and
responsible for an increasing share of productivity
and overall economic growth.
(Not everybody likes the name, by the way. We're okay with that.)
We're a small group of professional journalists dedicated to
bringing you the most important news about New England's role
in the exponential economy. More on our mission and team
here.
Share
